Tokyo, Japan – January 21, 2019 – LPixel Inc., a leader in image analysis and processing in life science and medical research, announced today that it has secured the Japanese Marketing Certification for the addition of the new function for EIRL basic (certification number: 230AGBZX00107000), in accordance with the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Law).
Following the Marketing Certification of the brain measurement functionalities issued last October, this addition will enable healthcare professionals extract and measure the volume of white matter hyperintensity of brain MRI. LPixel will prepare for the expansion of the nationwide deployment of EIRL basic for the coming spring.
EIRL is the collective name given to LPixel’s AI medical image diagnostic support technology. LPixel aims to provide solutions that enable a faster and more accurate diagnosis by implementing its unique algorithms to analyze medical big data, such as brain and breast MRI, chest X-rays, colonoscopy and pathology.
Founded in March 2014, LPixel is a University of Tokyo spin-off that hones its expertise in life science image analysis. LPixel unifies artificial intelligence and its image analysis technologies to develop and provide advanced software for researchers and professionals in the life science industry, including the medical, pharmaceutical and agricultural sectors. LPixel is currently working in collaboration with the University of Tokyo, the National Cancer Center Japan and other research institutions to further the development of its AI-powered medical diagnosis technology. For more information, please visit https://lpixel.net/en/.